<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="524">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>16/09/2005</approvaldate>
  <actrnumber>ACTRN12605000433606</actrnumber>
  <trial_identification>
    <studytitle>Dose-response to coenzyme Q10 supplementation with Q-Gel</studytitle>
    <scientifictitle>Change in plasma coenzyme Q10 level after various doses of the coenzyme Q10 supplement Q-Gel in healthy volunteers</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>None</healthcondition>
    <healthcondition>Healthy Volunteers</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Normal development and function of platelets and erythrocytes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Four different treatments are to be used in this study. 1)single oral dose of 60 mg of coenzyme Q10 supplement Q-Gel (2 x 30 mg capsules); 2) single oral dose of 150 mg of coenzyme Q10 supplement Q-Gel (5 x 30 mg capsules); 3) single oral dose of 300 mg of coenzyme Q10 supplement Q-Gel (10 x 30 mg capsules); 4) single oral dose of 300 mg of coenzyme Q10 supplement Q-Gel (3 x 100 mg capsules). Each participant will receive all four treatments, one per week for four weeks. 

Treatments will be given between 0800 and 0900 hours, after an overnight fast. For all doses, blood samples will be drawn at time 0, 2, 4, 6, 8, and 10 hours after the dose for the measurement of coenzyme Q10 in plasma. Lipid profiles (total cholesterol, LDL- and HDL-cholesterol and triglycerides) will also be measured on all samples.</interventions>
    <comparator />
    <control>Dose comparison</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The increase in plasma CoQ10 after supplementation with varying doses of the CoQ10 supplement Q-Gel, for a period of 10 hours after ingestion of the supplement</outcome>
      <timepoint>After ingestion of the supplement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The increase in plasma CoQ10 after supplementation given as 3 x 300 mg supplements and 10 x 30 mg, for a period of 10 hours after ingestion of the supplements, will be compared.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>30</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Smoker. Taking any supplements or prescription medication on a regular basis. Intercurrent illness.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>No allocation concealment is used</concealment>
    <sequence>Random letters (A-D), allocated one letter to each treatment were pulled from a hat</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Bio-availability</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>9/11/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>18</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Canterbury Health Laboratories</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>New Zealand Heart Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sarah Molyneux</name>
      <address>Biochemistry Unit
Canterbury Health Laboratories
PO Box 151
Christchurch 8001</address>
      <phone>+64 3 3641594</phone>
      <fax />
      <email>sarah.molyneux@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sarah Molyneux</name>
      <address>Biochemistry Unit
Canterbury Health Laboratories
PO Box 151
Christchurch 8001</address>
      <phone>+64 3 3641594</phone>
      <fax />
      <email>sarah.molyneux@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>